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Background: Aortic stenosis (AS) is responsible for significant morbidity, mortality, and health care costs. Data suggests that bisphosphonates may 
slow the progression of AS. We evaluate the effects of the bisphosphonate, ibandronate, on osteoblastic differentiation by aortic valve myofibroblasts 
(AVMF).
Methods: Porcine AVMF were isolated, grown to confluence, and then growth-arrested by incubation in serum-depleted medium. Cells were then 
cultured in the presence of control, transforming growth factor (TGF)-β (1.0 μg/ml; positive control), oxidized low-density lipoprotein (ox-LDL; 10 μg/
ml), and ibandronate (0.1 and 1.0 μM) in the presence of ox-LDL. Reverse transcription polymerase chain reaction and western blot analyses were 
used to assess expression of osteogenic markers.
Results: Ox-LDL and TGF-β upregulated AVMF expression of the osteogenic markers osteopontin, osteocalcin, and alkaline phosphatase. 
Ibandronate (0.1 and 1.0 μM) inhibited ox-LDL-induced expression of osteopontin, osteocalcin, and alkaline phosphatase in a dose-dependent 
manner (Figure). Ibandronate similarly reduced osteopontin protein expression.
Conclusion: Ibandronate prevents cholesterol-related induction of an osteogenic phenotype in AVMF. As aortic valve calcification is the final 
pathway in the development of calcific aortic valve disease and subsequent AS, these findings suggest that bisphosphonates may serve as a novel 
therapeutic agent in the management of AS.
